您的位置: 首页 >会议日程
邱妙珍
单位: 中山大学肿瘤医院 科室: 内科
简历:

除非特殊说明,请勿删除或改动简历模板中蓝色字体的标题及相应说明文字
参与者 简历
邱妙珍,中山大学,肿瘤防治中心,主治医师
教育经历(从大学本科开始,按时间倒序排序;请列出攻读研究生学位阶段导师姓名):
  2012/09-2015/06,中山大学,肿瘤防治中心,博士,导师:杨大俊
  2006/09-2008/06,中山大学,肿瘤防治中心,硕士(七年制),导师:徐瑞华
  2001/09-2006/06,中山大学,中山医学院临床医学系,本科,学士
 
科研与学术工作经历(按时间倒序排序;如为在站博士后研究人员或曾进入博士后流动站(或工作站)从事研究,请列出合作导师姓名):

  1. 2011/12-至今,中山大学,肿瘤防治中心,主治医师
  2. 2014/09-2016/07, University of Johns Hopkins,School of Medicine, 病理科,博士后
  3. 2008/08-2011/12,中山大学,肿瘤防治中心,住院医师
曾使用其他证件信息(申请人应使用唯一身份证件申请项目,曾经使用其他身份证件作为申请人或主要参与者获得过项目资助的,应当在此列明)

主持或参加科研项目(课题)及人才计划项目情况(按时间倒序排序):
  1. 国家自然科学基金青年科学面上项目,81772587,MDM2/p53小分子抑制剂APG-115对肠癌的抗肿瘤作用及其机制研究,2018/01-2021/12,52万元,在研,参与
  2. 国家自然科学基金青年科学基金项目,81602066,microRNA-375在胃癌PD-L1过表达中的作用和机制研究,2017/01-2019/12,17万元,在研,主持
  3. 中央高校基本科研业务费专项资金资助,16ykpy25,IFN-γ/JAK/STAT通路调控EBV阳性胃癌PD-L1过表达的机制研究,2016/01-2018/12,15万元,在研,主持
  4. 广东省食管癌研究所科技计划,Q201408,PD-1/PDL-1在食管鳞癌侵袭转移中的作用及其分子机制,2014/12-2016/12,5万元,已结题,主持
  5. 广东省医学科研基金,B2014161,HER2在胃癌中的表达:原发灶和转移灶、活检和手术标本的对比,2014/06-2016/05,1万元,已结题,主持
  6. 国家863生物大数据开发与利用关键技术研究,2015AA020103,常见恶性肿瘤大数据处理分析与应用研究,2015/01-2017/12,761万元,已结题,参与
  7. 广东省食管癌研究所科技计划,Q201405,MDM2-P53 小分子抑制剂逆转食管鳞状细胞癌化疗耐药性的研究,2014/12-2016/12,5万元,已结题,参与
  8. 广东省重大科技专项计划项目,2013A022100023,XIAP小分子抑制剂APG-1387的临床前研究,2014/01-2017/12,100万元,已结题,参与
  9. 国家自然科学基金,81372570,microRNA-214在结直肠癌肝转移中的作用和机制研究,2014/01-2017/12,72万元,已结题,参与
 
代表性研究成果和学术奖励情况(每项均按时间倒序排序)
(请注意:①投稿阶段的论文不要列出;②对期刊论文:应按照论文发表时作者顺序列出全部作者姓名、论文题目、期刊名称、发表年代、卷(期)及起止页码(摘要论文请加以说明);③对会议论文:应按照论文发表时作者顺序列出全部作者姓名、论文题目、会议名称(或会议论文集名称及起止页码)、会议地址、会议时间;④应在论文作者姓名后注明第一/通讯作者情况:所有共同第一作者均加注上标“#”字样,通讯作者及共同通讯作者均加注上标“*”字样,唯一第一作者且非通讯作者无需加注;⑤所有代表性研究成果和学术奖励中本人姓名加粗显示。)
   按照以下顺序列出:①10篇以内代表性论著;②论著之外的代表性研究成果和学术奖励。
  • 期刊论文
  1. Miaozhen Qiu#, Simei Shi#, Min Chen#, Jing Wang, Qinian Wu, Hui Sheng H, Huizhong Zhang, Jingping Yun, Zhiwei Zhou, Fenghua Wang*, Dajun Yang*, Ruihua Xu*.Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer, J Cancer, 2017,8(17):3531-3537.
  2. Miaozhen Qiu#, Dajun Yang*, Ruihua Xu*, Impact of marital status on survival of gastric adenocarcinoma patients: Results from the Surveillance Epidemiology and End Results (SEER) Database, Sci Rep, 2016, 6: 21098
  3. Miaozhen Qiu#, Jianming Hu#, Dajun Yang#, David Peter Cosgrove, Ruihua Xu*, Pattern of distant metastases in colorectal cancer: a SEER based study, Oncotarget, 2015, 6(36): 38658-38666
  4. Yuhong Li#, Miaozhen Qiu#, Jianming Xu#, Guoping Sun, Huishan Lu, Yunpeng Liu, Meizuo Zhong, Helong Zhang, Shiying Yu, Wei Li, Xiaohua Hu, Jiejun Wang, Ying Cheng, Juntian Zhou, Zengqing Guo, Zhongzhen Guan, Ruihua Xu*, S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study, Oncotarget, 2015, 6(33): 35107-35115
  5. Miaozhen Qiu#, Yixin Zhou#, Ying Jin, Zixian Wang, Xiaoli Wei, Hongyu Han, Wenfeng Ye, Zhiwei Zhou, Dongsheng Zhang, Fenghua Wang, Yuhong Li, Dajun Yang*, Ruihua Xu*, Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy, Supportive Care Cancer, 2015, 23(7):1933-1939
  6. Xiao-Li Wei#, Miao-Zhen Qiu#, Ying Jin#, Ya-xin Huang, Rui-yu Wang, Wei-Wei Chen, De-Shen Wang, Feng Wang, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu*, Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases, British journal of cancer, 2015: 31;112 Suppl:1283-90
  7. Miaozhen Qiu#, Yixin Zhou#, Xinke Zhang#, Zixian Wang, Fang Wang, Jianyong Shao, Jiabin Lu, Ying Jin, Xiaoli Wei, Dongsheng Zhang, Fenghua Wang, Yuhong Li, Dajun Yang*, Ruihua Xu*, Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients, BMC Cancer, 2014, 14:823
  8. Miao-zhen Qiu#, Qian Li#, Zhi-qiang Wang#, Tian-shu Liu, Qing Liu, Xiao-li Wei, Ying Jin, De-shen Wang, Chao Ren, Long Bai, Dong-sheng Zhang, Feng-hua Wang, Yu-hong Li, Rui-hua Xu*, HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation, International journal of cancer, 2014, 134(10):2468-2477
  9. Xiao-li Wei#, Miao-zhen Qiu#, Wei-wei Chen, Ying Jin, Chao Ren, Feng Wang, Hui-yan Luo, Zhi-qiang Wang, Dong-sheng Zhang, Feng-hua Wang, Yu-hong Li, Rui-hua Xu*, The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer, Journal of translational medicine, 2013, 11(1):249
  10. Miao-zhen Qiu#Mu-yan Cai#Dong-sheng ZhangZhi-qiang WangDe-shen WangYu-hong Li, Rui-hua Xu*, Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China, Journal of translational medicine, 2013,11:58
二、会议论文

三、专著

四、授权发明专利

五、会议特邀学术报告
 (1) Qiu Miaozhen, Programmed Cell Death Ligand 1 (PD-L1) Expression on Gastric cancer and Its Relationship with Clinicopathologic Factors, 2015 Global Academic Programs, Huston, Texas, USA, 14-16 April 2015
(2) Qiu Miaozhen, Efficacy and Safety of Capecitabine as Maintenance Treatment after First-line Chemotherapy using Oxaliplatin and Capecitabine in Advanced Gastric Adenocarcinoma Patients: A Prospective Observation.2014 Global Academic Programs, Seoul, Korea, 1-3 May 2014
 
 

... 更多
 
分享至:

学术任务如下:

日期 时间 会场 Session/主题 角色 姓名 单位
2018-08-19 15:50-16:00 四层 展览厅4BC会议室1

肿瘤流行病学&病因学分会场--第四单元:青年论坛

Frequency and clinic-pathologic features of metastasis to liver, lung, bone and brain from gastric cancer: a SEER based study
讲者

邱妙珍

中山大学肿瘤医院